Medical Publications


Medical Publications

The following information contains verifiable peer-reviewed manuscripts and abstracts on the use of Immunomedics compounds in development. Links to PubMed and other original sources are provided, where available

Study IMMU-132-01 (Sacituzumab govitecan Basket Study)

Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2 , Single-Arm, Basket Trial. Ann Oncol. 2020; S0923-7534(20)42445-7.

Santin AD, Komiya T, Goldenberg DM, et al. Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase 1/2 study. J Clin Oncol. 2020; 38 (suppl; abstr 6081)

Tagawa ST, Faltas M, Lam ET, et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. J Clin Oncol. 2019;39(suppl 7S):abstr 354.

Bardia A, Mayer IA, Vahdet LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741-751.

Bardia A, Diamond JR, Vahdat LT, et al. Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC). J Clin Oncol. 2018;36(15 suppl):1004.

Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123:3843-3854.

Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35:2790-2797.

Gray JE, Heist RS, Starodub AN, et al. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan. Clin Cancer Res. 2017;23:5711-5719.

Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21:3870-3878.

TROPHY-U-01 (Metastatic Urothelial Cancer Study)

Loriot Y, Balar AV, Petrylak DP, et al. TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI). Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Grivas P, Sternberg CN, Agarwal N, et al. TROPHY-U-01 Cohort 3: Sacituzumab Govitecan (SG) and Pembrolizumab (Pembro) in Patients (pts) With Progression or Recurrence of Metastatic Urothelial Cancer (mUC) After Platinum (PLT)-Based Therapy. Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274

Petrylak DP, Tagawa ST, Jain RK, et al. Early Results of TROPHY-U-01 Cohort 2: Sacituzumab Govitecan (SG) in Platinum-Ineligible Patients (pts) With Metastatic Urothelial Cancer (mUC) Who Progressed After Prior Checkpoint Inhibitor (CPI) Therapy. J Clin Oncol. 2020; 38 (suppl; abstr 5027).

Tagawa ST, Balar A, Petrylak DP, Grivas P, et al. Initial Results From TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients (Pts) With Metastatic Urothelial Cancer (mUC) After Failure of Platinum-Based Regimens (PLT) or Immunotherapy. Annals of Oncology (2019) 30 (suppl_5): v851-v934.10.1093/annonc/mdz394.

Tagawa ST, Petrylak DP, Grivas P, et al. TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy. J Clin Oncol.2019; 37 (suppl; abstr TPS3153).

Sacituzumab Govitecan Preclinical Publications

Cardillo TM, Rossi DL, Zalath MB, et al. Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer. Oncotarget. 2020;11:3849-3862

Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989-29006

Cardillo TM, Sharkey RM, Rossi DL, et al. Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer. Clin Cancer Res. 2017;23:3405-3415

Chang CH, Wang Y, Zalath M, et al. Combining ABCG2 inhibitors with IMMU-132, an anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to sn-38 in breast and gastric cancers. Mol Cancer Ther. 2016;15(8):1910-1919

Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919-931

Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget.2015;6:22496-22512

Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan).Clin Cancer Res. 2015;21:5131-5138

Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011;17:3157-3169

Govindan SV, Stein R,* Qu Z, Chen S,* Andrews P,* Ma H, Hansen HJ, Griffiths GL, Horak ID, Goldenberg DM. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat. 2004;84:173-182

Sharkey RM,* Karacay H,* Govindan SV, Goldenberg DM. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol Cancer Ther. 2011;10:1072-1081